-
Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its novel antibody-drug conjugate (ADC), 9MW2921. Next-Generation ADC Based on Mabwell’s IDDC Platform9MW2921 is a next-generation ADC that leverages…
-
Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally
•
Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of millions of US dollars in a Series A financing round. Lake Bleu Capital led the investment, with participation from Asia Pacific Medical Group. The funds will be directed towards the company’s globalization strategy, with a…
-
TransThera Sciences’ TT-00420 Receives Breakthrough Designation for Cholangiocarcinoma Treatment
•
The Center for Drug Evaluation (CDE) website has indicated that Nanjing-based TransThera Sciences (Nanjing), Inc.’s candidate TT-00420 is set to receive breakthrough therapy designation (BTD) for the treatment of unresectable advanced or metastatic cholangiocarcinoma. This designation is for patients whose disease recurs after previous systemic chemotherapy and/or FGFR inhibitor treatment.…
-
Shenzhen Salubris Pharmaceuticals’ SAL0120 for IgA Nephropathy Accepted for NMPA Review
•
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial filing for the small molecule SAL0120, which is indicated for the treatment of IgA nephropathy. SAL0120: An Endothelin Receptor Antagonist for Chronic Kidney Disease and HypertensionSAL0120, an in-house developed…
-
NHSA Unveils 2023 Flying Inspection Plan for Medical Insurance Fund Oversigh
•
The National Healthcare Security Administration (NHSA) has released its 2023 Basic Medical Insurance (BMI) Fund Flying Inspection Plan, following a report on the impact of such efforts in hospitals during 2022. This year’s inspections will concentrate on medical imaging, clinical examination, and rehabilitation services, focusing on the use and management…
-
Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its bispecific antibody, MCLA-129, in combination with befotertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The treatment…
-
Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina
•
Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III clinical trial evaluating the efficacy of its quadrivalent influenza modified RNA (modRNA) vaccine in comparison to a conventional quadrivalent influenza vaccine. This double-blind study aims to recruit between 1,500 to 2,000 participants who are above…
-
Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment
•
China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient dosing in the global regulatory Phase III FORTITUDE-101 trial for its drug candidate bemarituzumab, which is being studied for the treatment of first-line gastric cancer in China. Bemarituzumab’s Mechanism and Potential ImpactBemarituzumab is a potential…
